Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin for prevention of recurrent hypertensive disorders of pregnancy
jRCTs031230067Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pravastatin and aspirin in maternal hypertension (HDP), preeclampsia and pregnancy-induced hypertension (PIH) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of hypertensive disorders of pregnancy. Started May 2023; status: active, not recruiting.
02
Drugs
pravastatinaspirin
03
Conditions
maternal hypertension (HDP)preeclampsiapregnancy-induced hypertension (PIH)
Beyond the preview
Go deeper on jRCTs031230067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230067.